TRT Receives Defense Acquisition Challenge Grant
2008-11-17 21:49:00 -
www.trtllc.com - Tissue Regeneration Technologies, LLC (TRT) is proud to announce the receipt of a $2 million grant from the Defense Acquisition Challenge (DAC) for fiscal year 2009. TRT's proposal "Shockwave Therapy for Traumatic Wounds of the Extremity" is designed to evaluate the effectiveness of shockwave therapy in treating complex wounds in a combat casualty care venue. TRT's Department of Defense partner, the Combat Wound Initiative (CWI) Program, is currently spearheading a randomized clinical trial evaluating the efficacy of shock wave therapy.
The Combat Wound Initiative Program in partnership with the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), submitted a competitive grant proposal to the DAC, which was one of four selected from 300 proposals submitted.
The DAC grant funds will allow the CWI Program to expand its clinical trial to Brooke Army Medical Center in San Antonio, Johns Hopkins Hospital in Baltimore, and the University of Alabama at Birmingham.
Members of the CWI Program, HJF, and TRT's management team attended the Foreign Comparative Testing / DAC Kickoff ceremony at the Army Navy Country Club in Arlington, Virginia where more than 200 senior military staff as well as the Under Secretary of the Army were briefed on the projects selected for field testing in 2009.
The primary function of the Defense Acquisition Challenge is to accelerate field testing for technologies demonstrating potential for direct war fighter benefit. If field testing is successful, the DAC expects rapid procurement of these advanced technologies into the U.S. military in order to deliver the latest and best technology to America's war fighters at cost savings or cost avoidance to the U.S. government.
The CWI-HJF-TRT proposal achieves these objectives by providing cutting-edge MultiWaveTM technology at significant potential cost savings over the current standard of combat casualty wound care. TRT's technology may benefit American war fighters by accelerating tissue repair in wounds and minimizing the number of surgical interventions, thereby reducing hospital time and cost.
"This project is the culmination of extraordinary efforts by the U.S. Army, Research, Development and Engineering Command, Henry Jackson Foundation, Walter Reed Army Medical Center, National Naval Medical Center and TRT employees. We are honored to be involved in such a worthy endeavor," stated John Warlick, TRT's Chief Executive Officer.
"Our heroic soldiers deserve the best wound care available and we are extremely proud to be the company that may indeed provide it."
About TRT
TRT is an international medical device company established to develop, manufacture and sell MultiWaveTM devices to treat various conditions poorly served by the current standard of care. TRT is headquartered in Woodstock, Georgia from which it also operates its cardiac subsidiary, Cardiac Regeneration Technologies. Production of TRT"s devices is handled by its manufacturing subsidiary, MTS Europe GmbH, located in Konstanz, Germany.
TRT is currently conducting FDA trials with its DermaGold" MultiWave" device for the treatment of wounds as well as plantar fasciitis. TRT has FDA clearance to market its LithoGoldTM lithotripsy system for treatment of kidney and ureteral stones. TRT devices are CE approved and distributed in approximately 20 countries worldwide. For more information, please visit the company"s website at cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww ...
TRT
John Warlick, 770-966-1315
mailto:jwarlick@trtllc.com
